ClinicalTrials.gg
Not yet recruitingNCT07941453PACT-PCVUpdated Nov 17, 2026

Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage

A Phase 4 interventional study of Anti-VEGF agents and tissue plasminogen activator (rtPA) in Polypoidal Choroidal Vasculopathy (PCV) and Submacular Hemorrhage, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting. Open to participants aged 45 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
45 Years to 95 Years
Sex
All
01

Study summary

The goal of this randomized clinical trial is to determine whether adding recombinant tissue plasminogen activator (rtPA), a clot-dissolving medicine, to gas injection and anti-VEGF treatment improves outcomes in people with submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV).

The main questions it aims to answer are:

  • Does adding rtPA increase the proportion of participants with complete displacement of blood from beneath the fovea, the center of the macula, at 1 week after treatment?
  • Does adding rtPA improve vision at 6 months and reduce complications, particularly vitreous hemorrhage (bleeding into the gel inside the eye) within 1 month after treatment?

Researchers will compare two pneumatic displacement (PD) strategies: anti-VEGF treatment plus C3F8 gas and rtPA (triple PD) and anti-VEGF treatment plus C3F8 gas without rtPA (dual PD). This comparison will assess the additional benefits and risks of rtPA. The study will enroll 80 participants at a single center. Participants will be randomly assigned to one of the two groups, with an equal chance of receiving either treatment.

The primary outcome is complete SMH displacement at 1 week, defined as no remaining blood beneath the fovea on optical coherence tomography (OCT), a scan that produces detailed images of the retina. Secondary outcomes include changes in best-corrected vision at 6 months, vitreous hemorrhage within 1 month, retinal detachment and other serious complications during follow-up, and the number of anti-VEGF injections over 6 months.

Participants will:

  • Undergo baseline eye examinations, vision testing, and retinal imaging.
  • Receive injections of anti-VEGF medicine and C3F8 gas into the affected eye, with or without rtPA, according to their assigned group.
  • Follow the prescribed face-down positioning instructions for 3 days after treatment.
  • Attend follow-up visits at 1 week and at 1, 3, and 6 months after treatment for vision testing, eye examinations, and retinal imaging, and receive further anti-VEGF treatment as needed.
02

Conditions studied

  • Polypoidal Choroidal Vasculopathy (PCV)
  • Submacular Hemorrhage
03

In context

Polypoidal Choroidal Vasculopathy

55 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 7 are open to participants now.

This study's planned enrollment of 80 is above the median of 50 across 40 interventional studies indexed under Polypoidal Choroidal Vasculopathy.

Browse Polypoidal Choroidal Vasculopathy studies →

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 106 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fovea-involving submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV), with a hemorrhage area of ≥2 optic disc areas and a subfoveal clot thickness of ≥300 μm.
  • An interval of ≤14 days between symptom onset and planned treatment.
  • Willingness to participate in the study and provision of written .

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to undergo pneumatic displacement (PD).
  • A history of previous SMH.
  • Untreated retinal tears, retinal degenerative lesions, or other ocular conditions that make PD unsuitable.
  • Concurrent significant vitreous hemorrhage that interferes with postoperative examination and treatment outcome assessment.
  • Previous vitrectomy or other ocular surgery that may affect macular structure or the assessment of visual function.
  • Coexisting ocular diseases, such as severe cataract, glaucoma, or uveitis, that may interfere with postoperative visual acuity assessment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Triple PD (Anti-VEGF + Gas + rtPA)

    Intravitreal injection of an anti-VEGF agent, intravitreal injection of rtPA (off-label), and intravitreal gas injection for pneumatic displacement.

    Drug: Anti-VEGF agents · Drug: tissue plasminogen activator (rtPA) · Procedure: Pneumatic displacement with intravitreal gas

  • Active comparator
    Dual PD (Anti-VEGF + Gas)

    Intravitreal injection of an anti-VEGF agent and intravitreal gas injection for pneumatic displacement.

    Drug: Anti-VEGF agents · Procedure: Pneumatic displacement with intravitreal gas

Interventions

  • DrugAnti-VEGF agents

    Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage.

  • Drugtissue plasminogen activator (rtPA)

    Intravitreal injection of rtPA as an off-label adjunct to pneumatic displacement, administered only in the triple PD arm at the dose specified in the study protocol, to promote clot liquefaction and facilitate submacular hemorrhage displacement.

  • ProcedurePneumatic displacement with intravitreal gas

    Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms.

06

What researchers measure

Primary outcomes

  1. Rate of complete SMH displacement at 1 week after the procedure.

    No residual submacular hemorrhage in the foveal area on OCT.

    Time frame: 1 week after procedure

Secondary outcomes

  1. Incidence of vitreous hemorrhage (VH) and proportion undergoing vitrectomy due to VH within 1 month after the procedure

    Incidence of vitreous hemorrhage within 1 month after the procedure and the proportion of participants requiring pars plana vitrectomy (PPV) because of vitreous hemorrhage.

    Time frame: Within 1 month after the procedure

  2. Incidence of severe postoperative complications, including retinal detachment

    Incidence of severe complications after the procedure, including retinal detachment.

    Time frame: Within 3 months after the procedure

  3. Change in best-corrected visual acuity (BCVA) at 6 months

    Change from baseline in best-corrected visual acuity (BCVA) at 6 months after the procedure, to assess visual prognosis.

    Time frame: At 6 months after the procedure

  4. Macular anatomical outcomes at 6 months

    Recovery of macular anatomy at 6 months after the procedure, including central macular thickness (CMT) , pigment epithelium detachment (PED) volume, and SMH absorption/resolution, to assess anatomical prognosis.

    Time frame: At 6 months after the procedure

  5. Number of anti-VEGF injections within 6 months after the procedure

    Total number of anti-VEGF injections administered within 6 months after the procedure.

    Time frame: Within 6 months after the procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jun 2029, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941453
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Fang Zheng
Contact
tjmuzxf@163.com
+86 18258499106

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion